Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Transplantation. 2009 Apr 15;87(7):983–991. doi: 10.1097/TP.0b013e31819c86ea

FIGURE 1.

FIGURE 1

Macroencapsulated β-cells derived from human fetal islet-like cell clusters (ICCs) survive and replicate. (A) Schematic representation of a cross section through a cell-filled TheraCyte encapsulation device; immunohistochemical analysis of a representative human ICC-filled device explanted 10 weeks after placement; insulin (red) n = 5, scale bar: 15 µm. (B) Immunohistochemical analysis of islet hormones; insulin (red), glucagon (green), and somatostatin (green) in human ICCs in vitro (n = 3), 10 weeks after transplantation into the renal compartment (RC, n = 3), or in device placed subcutaneously (Device, n = 5), scale bar: 15 µm. (C) Quantitation of insulin-positive cell fractions in human ICCs before (in vitro, n = 3, black bar) and 10 weeks after transplantation in device (Device, n = 3, white bar) or control transplantation (RC, n = 3, gray bar). (D) Immunostaining for insulin (red) and proliferation marker Ki67 (green) in devices or RC grafts explanted after 10 weeks. Arrows depict Ki67+/insulin = cells, scale bar: 50 µm, magnified insets, scale bar: 5 µm. (E) Quantitation of mitotic index in control (RC, n = 3) and device transplants (Device, n = 3), P values *less than 0.05, **less than 0.01. Blue nuclear counterstain in A, B, and D is DAPI.